

YR0131

Leader in Biomolecular Solutions for Life Science



Human CD20 Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0131

Basic Information

Molecular Weight

150 kDa

Endotoxin

<0.05EU/mg (<0.00005EU/μg)

Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Obinutuzumab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Human CD20

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 6.0

Contact



www.abclonal.com

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)